Current recommendations about the diagnosis and treatment of testosterone deficit syndrome: Clinical guidelines;Recomendaciones actuales sobre el diagnóstico y tratamiento del sdt: guías de práctica clínica

Archivos Espanoles de Urologia

Volumn 66, Issue 7, 2013, Pages 737-744

  Rosa, José Valero ^a   López, Javier Márquez ^a   Hernández, Pablo Campos ^a   Martínez, Ana Puigvert ^b   Castro, Rafael Prieto ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b IAMDROMS   (Spain)

Author keywords

Diagnosis; Hypogonadism; Testosterone; Treatment

Indexed keywords

TESTOSTERONE;

AGED; ARTICLE; CASE REPORT; HUMAN; HYPOGONADISM; MALE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE;

AGED; GUIDELINES AS TOPIC; HUMANS; HYPOGONADISM; MALE; PHYSICAL EXAMINATION; PRACTICE GUIDELINES AS TOPIC; TESTOSTERONE;

EID: 84883725950     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ et al: Investigation, Treatment, and Monitoring of Late-Onset Hypogonasdism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol 2009; 55: 121-30
2. Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, de Ronde W. Guidelines on male hypogonadism. EAU 2012
3. Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab 2008; 93(10):3870-7.
4. Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92(2):405-13.
5. Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE.Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status.Maturitas. 2005; 14;50(2):124-33.
6. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004; 89(8):3813-7.
7. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49(9):1239-42.
8. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 8;363(2):123-35.
9. Lunemfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recomendacations for the investigation, treatment and monitoring o late-onset-hypogonadism in males: scientific back ground and rationales. Aging Male.2005;8:59-74.
10. Bhasin S,Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011; 96(8):2430-9.
11. Vesper HW,Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids 2009; 74(6):498-503.
12. Dobs AS, Few WL 3rd, Blackman MR, et al. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996; 81(11):4108-12.
13. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81(12):4358-65.
14. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. The Clin Risk Manag 2009; 5(3):427-48.
15. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A BiolSci Med Sci 2005; 60(11):1451-7.
16. Parsons JK, Carter HB, Platz EA, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005; 14(9):2257-60.
17. Zitzman M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscolar testosterone undecanoate therapy in hipogonadal men. J Clin Endocrinol Metab 2007; 92(10):3844-53.
18. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281(6):E1172-81.
19. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocr 2011; 165(5):675-85.
20. Isidori AM, Giannetta E, Greco EA et al. Effects of testosterone on body composition, body metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63(3):280-93.
21. Haider A, Gooren LJ, Padungton P, et al. Improvement of the metabolic syndrome and of nonalcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes 2010; 18(3):167-71.
22. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154(6):899-906.
23. Moon du G, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido®)in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 2010; 7(6):2253-60.
24. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case report. J Sex Med 2006; 3(4):727-35.